N
Noveome Biotherapeutics
A clinical stage company focused on breakthrough therapies for the regenerative repair of inflamed or damaged tissues
About Noveome Biotherapeutics
Noveome Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation biologics. The company's core product, ST266, is a biologic with unique and powerful healing potential, currently being tested in Phase I clinical trials for COVID-19 and various ophthalmic indications. Noveome operates in the biopharmaceutical market, targeting healthcare providers and patients in need of advanced treatments for serious conditions. The business model revolves around research and development, clinical trials, and eventual commercialization of their biologic products. Revenue is generated through partnerships, grants, and future sales of approved treatments. Noveome's innovative Cribriform Targeted Device (CT6) enhances drug delivery to the nasal cavity, ensuring high absorption and efficacy. The company is headquartered in Pittsburgh, PA, and is driven by a passionate team dedicated to making a positive impact on lives.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES EOther financing | Apr 2025 | $51M | $204M | MAK Capital | ↗ |
| SERIES EOther financing | Aug 2023 | $21M | $83M | MAK Capital | ↗ |
Growth signals
Latest recorded traffic for Noveome Biotherapeutics is 2.8K monthly website visits, up 75% over the last three months. Noveome Biotherapeutics's team grew 3.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
Aiolos BioRevolutionizing the treatment landscape for respiratory disease and other immune conditions |
San Francisco, United States | Acquired | 3 | $245M | $1B |
Lirum TherapeuticsClinical-stage targeted therapies for oncology and autoimmune diseases |
New York City, United States | Operational | |||
K PharmaInnovating medical treatments with iPS cell-based drug discovery and regenerative solutions |
Tokyo, Japan | Operational | |||
Txinno BioscienceBiotech & Life Sciences |
Yongin-si, South Korea | Operational | |||
mAbProteinInnovative antibody research and clinical solutions enhancing patient care and regional development |
Tokyo, Japan | Operational | |||
LiberotheraDrug discovery platform targeting complex membrane proteins |
Tokyo, Japan | Operational | |||
MiraBiologicsBringing the miracle in medicine for a better future/mirai to the lives of people |
Tokyo, Japan | Operational | |||
KirkstallAdvanced organ-on-a-chip dynamic cell culture systems |
York, United Kingdom | Acquired |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Noveome Biotherapeutics in the O'Hara Township ecosystem
The Noveome Biotherapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
US Department of Health and Human Services
US Department of War
Government of Pennsylvania
Series B and later2 investors entered at this stage
Miraki Innovation- MCMAK Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Noveome Biotherapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Noveome Biotherapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








